Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1986 1
1991 1
1992 1
1997 1
2002 1
2004 1
2005 2
2006 2
2007 4
2009 2
2010 4
2012 4
2013 1
2014 5
2015 3
2016 4
2017 3
2018 5
2019 6
2020 12
2021 18
2022 16
2023 20
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

105 results

Results by year

Filters applied: . Clear all
Page 1
The future of immunotherapy for sarcoma.
Tsukahara T, Emori M, Murata K, Mizushima E, Shibayama Y, Kubo T, Kanaseki T, Hirohashi Y, Yamashita T, Sato N, Torigoe T. Tsukahara T, et al. Among authors: murata k. Expert Opin Biol Ther. 2016 Aug;16(8):1049-57. doi: 10.1080/14712598.2016.1188075. Epub 2016 May 27. Expert Opin Biol Ther. 2016. PMID: 27158940 Review.
Identification of antigenic epitopes recognized by tumor infiltrating lymphocytes in high grade serous ovarian cancer by multi-omics profiling of the auto-antigen repertoire.
Millar DG, Yang SYC, Sayad A, Zhao Q, Nguyen LT, Warner K, Sangster AG, Nakatsugawa M, Murata K, Wang BX, Shaw P, Clarke B, Bernardini MQ, Pugh T, Thibault P, Hirano N, Perreault C, Ohashi PS. Millar DG, et al. Among authors: murata k. Cancer Immunol Immunother. 2023 Jul;72(7):2375-2392. doi: 10.1007/s00262-023-03413-7. Epub 2023 Mar 21. Cancer Immunol Immunother. 2023. PMID: 36943460 Free PMC article.
Cisplatin resistance driver claspin is a target for immunotherapy in urothelial carcinoma.
Yamada S, Miyata H, Isono M, Hori K, Yanagawa J, Murai A, Minowa T, Mizue Y, Sasaki K, Murata K, Tokita S, Nakatsugawa M, Iwabuchi S, Hashimoto S, Kubo T, Kanaseki T, Tsukahara T, Abe T, Shinohara N, Hirohashi Y, Torigoe T. Yamada S, et al. Among authors: murata k. Cancer Immunol Immunother. 2023 Jul;72(7):2057-2065. doi: 10.1007/s00262-023-03388-5. Epub 2023 Feb 16. Cancer Immunol Immunother. 2023. PMID: 36795123
[Cancer immunotherapy and immunological memory].
Murata K, Tsukahara T, Torigoe T. Murata K, et al. Nihon Rinsho Meneki Gakkai Kaishi. 2016;39(1):18-22. doi: 10.2177/jsci.39.18. Nihon Rinsho Meneki Gakkai Kaishi. 2016. PMID: 27181230 Free article. Review. Japanese.
Fusion with type 2 macrophages induces melanoma cell heterogeneity that potentiates immunological escape from cytotoxic T lymphocytes.
Minowa T, Hirohashi Y, Murata K, Sasaki K, Handa T, Nakatsugawa M, Mizue Y, Murai A, Kubo T, Kanaseki T, Tsukahara T, Iwabuchi S, Hashimoto S, Ishida-Yamamoto A, Uhara H, Torigoe T. Minowa T, et al. Among authors: murata k. J Pathol. 2023 Jul;260(3):304-316. doi: 10.1002/path.6083. Epub 2023 May 3. J Pathol. 2023. PMID: 37138382
Addressing the gap in clinical research education: Implementation of the Introduction to Clinical Research Training-Japan program.
Moromizato T, Garcia-Larsen V, Soeteman D, Wickner PG, Havens JM, Lund R, Eriguchi R, Tokuda Y, Murata K, Iseki K, Singh AK, Christopher KB. Moromizato T, et al. Among authors: murata k. J Gen Fam Med. 2018 Sep 15;19(6):188-190. doi: 10.1002/jgf2.204. eCollection 2018 Nov. J Gen Fam Med. 2018. PMID: 30464864 Free PMC article. No abstract available.
105 results